Investing.comCodex · 实盘不做把握 6/10
北京时间·🕒 发布 15:04:41时区推断·⟳ 抓取 15:05:57·⚡ 决策 07-29 15:07:40 +1m43s·90.5 天前
欧盟批准艾伯维 Rinvoq 用于重度斑秃新适应症
欧盟批准本身对 Rinvoq 是新增适应症利好，但 2026-06-29 CHMP 已给出正面意见，最终欧委会批准属于预期内程序落地。
📄 原文Investing.com↗ 原文
EU approves AbbVie’s Rinvoq for severe alopecia areata
Iran fires missiles at U.S. forces in Middle East, ending ceasefire lull NORTH CHICAGO, Ill. - AbbVie (NYSE:ABBV) annou…
不做 艾伯维（ABBV.US）
欧委会批准是 6 月 CHMP 正面意见后的预期内程序落地；AbbVie 体量大、Rinvoq 已是 83 亿美元级产品，斑秃新增标签未披露足够收入增量，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- AbbVie 已公告 CHMP 对 Rinvoq 重度斑秃适应症给出正面意见，并提示欧委会最终决定预计未来数月内作出。
- EMA 记录显示 CHMP 已建议 Rinvoq 增加重度斑秃适应症，说明监管方向已在批准前公开。
- Investing.com 报道欧委会已正式批准 Rinvoq 用于 12 岁及以上重度斑秃患者。市场反应:美股当时盘前未进入连续交易，未见可执行价差证据。
关键理由
- 欧盟批准本身对 Rinvoq 是新增适应症利好，但 2026-06-29 CHMP 已给出正面意见，最终欧委会批准属于预期内程序落地。
- Rinvoq 2025 年全球销售额约 83.04 亿美元、AbbVie 2025 年总收入约 611.60 亿美元；重度斑秃适应症未披露销售指引，短线增量相对 AbbVie 市值和收入基数难以构成重定价。
- 欧盟斑秃市场已有 Pfizer Litfulo 和 Lilly Olumiant 等 JAK 竞品，Rinvoq 虽扩大标签但不是无竞争独占市场。
主要风险
- 若后续 FDA 同步批准并伴随管理层上调 Rinvoq 销售峰值指引，才可能形成新的可交易增量。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-06-29 · 影响 weakens
核心利好已在 CHMP 正面意见阶段公开，且欧盟已有同适应症竞品。
检索:Rinvoq severe alopecia areata EU CHMP positive opinion June 2026 competitor Litfulo Olumiant 原文 ↗
原文全文
展开原文 · 1,939 字
Iran fires missiles at U.S. forces in Middle East, ending ceasefire lull
NORTH CHICAGO, Ill. - AbbVie (NYSE:ABBV) announced today that the European Commission has approved Rinvoq (upadacitinib) for treating severe alopecia areata in adults and adolescents aged 12 years and older, according to a press release statement.
The approval covers two dosage strengths of the JAK inhibitor: 15 mg and 30 mg, taken once daily. Rinvoq becomes the first JAK inhibitor approved for this indication in the European Union.
The approval was based on data from the Phase 3 UP-AA clinical program (M23-716), which included two replicate, randomized, placebo-controlled, double-blind studies. The trials enrolled 1,399 participants with severe alopecia areata, ages 12 to 64, across 248 sites worldwide.
Both the 15 mg and 30 mg doses met the primary endpoint of achieving a Severity of Alopecia Tool (SALT) score of 20 or less at week 24, indicating at least 80% scalp hair coverage. Key secondary endpoints were also met, including complete scalp hair regrowth (SALT = 0) at week 24.
The safety profile of both doses in the trial period was generally consistent with that observed in approved indications, the company stated.
Alopecia areata is an autoimmune disease that causes varying patterns of hair loss, from sudden bald patches on the scalp to complete loss of all body hair. According to a population-based study cited in the release, patients with alopecia areata face up to 40% higher risk of being diagnosed with new-onset depression and anxiety compared to the general population.
Rinvoq is already approved in the European Union for treating multiple conditions, including atopic dermatitis, rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, Crohn’s disease, and non-segmental vitiligo in various patient populations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
NORTH CHICAGO, Ill. - AbbVie (NYSE:ABBV) announced today that the European Commission has approved Rinvoq (upadacitinib) for treating severe alopecia areata in adults and adolescents aged 12 years and older, according to a press release statement.
The approval covers two dosage strengths of the JAK inhibitor: 15 mg and 30 mg, taken once daily. Rinvoq becomes the first JAK inhibitor approved for this indication in the European Union.
The approval was based on data from the Phase 3 UP-AA clinical program (M23-716), which included two replicate, randomized, placebo-controlled, double-blind studies. The trials enrolled 1,399 participants with severe alopecia areata, ages 12 to 64, across 248 sites worldwide.
Both the 15 mg and 30 mg doses met the primary endpoint of achieving a Severity of Alopecia Tool (SALT) score of 20 or less at week 24, indicating at least 80% scalp hair coverage. Key secondary endpoints were also met, including complete scalp hair regrowth (SALT = 0) at week 24.
The safety profile of both doses in the trial period was generally consistent with that observed in approved indications, the company stated.
Alopecia areata is an autoimmune disease that causes varying patterns of hair loss, from sudden bald patches on the scalp to complete loss of all body hair. According to a population-based study cited in the release, patients with alopecia areata face up to 40% higher risk of being diagnosed with new-onset depression and anxiety compared to the general population.
Rinvoq is already approved in the European Union for treating multiple conditions, including atopic dermatitis, rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, Crohn’s disease, and non-segmental vitiligo in various patient populations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。